Introduction and Objective: Diabetic vasculopathy is a major complication of type 2 diabetes (T2DM), and endothelial senescence is a key driver of endothelial dysfunction and impaired angiogenesis. We tested whether ANGPTL8 promotes endothelial senescence in T2DM and explored the underlying mechanism.Methods: HUVECs were treated with recombinant ANGPTL8. qPCR assessed P21, P53, senescence-associated secretory phenotype genes […]
Read MoreCategory: Diabetes
1027-OR: Differences in Thymocyte Development in Human Immune System Mice Derived from Type 1 Diabetic and Healthy Control Hematopoietic Stem Cells
Introduction and Objective: In NOD mice, impaired T cell development and negative selection are implicated in disease development. However, in T1D patients, it remains unknown whether abnormalities in thymic selection contribute to disease development. Our knowledge of human T Cell Receptor (TCR) repertoire formation is limited by lack of access to human thymi. Thus, humanized […]
Read More2710-LB: Lipolysis Inhibition Induces Alterations in the Proteomic Landscape of Serum from Mice Exposed to Electronic Cigarettes
Introduction and Objective: E-cigarette use has become highly popular among youth and adults. This study examined how electronic cigarette exposure alters the serum proteome in mice and explored the role of nicotine-induced lipolysis in these changes. We have observed impaired cardiac function and increased oxidative stress following e-cigarette exposure. We hypothesized that lipolysis triggers systemic […]
Read More1874-P: Closed-Loop Technology in Acute Care: A Systematic Review and Meta-Analysis
Introduction and Objective: While closed-loop (CL) technology has transformed outpatient diabetes care, evidence in acute settings is limited. This systematic review and meta-analysis (PROSPERO: CRD420251133486) evaluated the safety, efficacy, and implementation of closed-loop technology in acute care.Methods: Eligible studies included adults managed with CL in acute care reporting glycaemic, safety, and implementation outcomes compared with […]
Read More2709-LB: Sustained Hyperglycemia Alters Endothelial Mechanical Organization over Time
Introduction and Objective: Diabetes Mellitus is strongly associated with vascular complications. While molecular mechanisms of hyperglycemia-induced vascular dysfunction have been extensively studied, the organization of mechanical forces within endothelial monolayers under sustained hyperglycemia remains poorly defined. We investigated whether prolonged hyperglycemia alters endothelial force organization over time.Methods: Human Umbilical Vein Endothelial Cells were cultured in […]
Read More2479-P: Synergistic Metabolic and Hepatic Benefits of Dorzagliatin and Resmetirom in MASLD Mice
Introduction and Objective: MASLD prevalence has increased to ~38% globally, with over 65% of people with MASLD having concomitant T2DM. This study evaluated whether combining dorzagliatin (glucokinase activator) and resmetirom (THR-β agonist) provides synergistic metabolic and hepatic benefits in a mouse model of MASLD.Methods: Male DIO mice with confirmed MASLD were randomized to receive dorzagliatin, […]
Read More2708-LB: Integrated Cardiovascular Risk Assessment in Young Adults with Type 2 Diabetes: The “YOUNG DIABETES” Program
Introduction and Objective: Early-onset type 2 diabetes (T2D) is associated with a more adverse cardiometabolic profile and increased cardiovascular (CV) risk. We aimed to characterize cardiovascular risk and subclinical atherosclerosis in young adults with T2D participating in the YOUNG DIABETES program.Methods: Observational study including individuals with T2D diagnosed at ≤50 years and current age ≤55 […]
Read More2474-P: Comparable Hepatic Benefits with Differential Effects on Triglycerides and Glycemic Control: A 24-Week Prospective Study
Introduction and Objective: Metabolic Associated Steatotic Liver Disease (MASLD) frequently coexists with type 2 diabetes mellitus (T2DM) and obesity and represents a major unmet clinical need, particularly with respect to therapies that improve both hepatic and metabolic outcomes. Comparative data between saroglitazar (SARO) and dapagliflozin (DAPA) in MASLD are limited.Methods: A 24-week, prospective, multicenter, open-label, […]
Read More2706-LB: Short Duration, High Risk: Poor Metabolic Profile Drives Complications More than Diabetes Duration
Introduction and Objective: Diabetes duration is considered a primary risk factor, yet some long-standing diabetics remain complication-free while recent-onset patients develop rapid damage. We investigated whether metabolic profile (triglycerides, BMI) could override traditional duration-complication relationships in community-based type 2 diabetes.Methods: Analysis of 400 T2DM patients stratified by duration (<5y n=142, 5-10y n=158, >10y n=100) and […]
Read More1713-P: AT7687, a Novel GIP-Receptor Antagonist, Combined with Cagrilintide, Leads to Robust Weight Loss and Substantial Improvements in Insulin Sensitivity and Body Composition in Obese Insulin-Resistant Monkeys
Introduction and Objective: AT7687 is a novel GIP receptor (GIPR) peptide antagonist being developed for weight management and cardiometabolic disease. Cagrilintide is a dual amylin and calcitonin receptor (CTR) agonist with established weight-lowering efficacy. To assess the therapeutic potential of combining GIPR antagonism with amylin/CTR agonism, a chronic study was conducted in non-human primates (NHPs).Methods: […]
Read More